Neurocrine Biosciences Reports Second Quarter 20...(009 2008 ...)

Date:7/29/2009

009 2008 ---- ---- ---- ---- (unaudited) (unaudited) Revenues: Sponsored research and development $3 $4 $20 $16 License fees and milestones 730 730 1,460 2,460 Grant revenue - - - 9 --- --- --- --- Total revenues 733 734 1,480 2,485 Operating expenses: Research and development 10,808 16,186 21,656 30,413 General and administrative 4,827 4,665 9,022 12,951 Cease use expense 941 - 5,769 - --- --- ----- --- Total operating expenses 16,576 20,851 36,447 43,364 Loss from operations (15,843) (20,117) (34,967) (40,879) Other income and (expense): Interest income and other income 563 1,060 22 2,666 Interest expense - (1,914) - (3,835) --- ------- --- ------- Total other income (expense) net 563 (854) 22 (1,169) Net loss $(15,280) $(20,971) $(34,945) $(42,048) ======== ======== ======== ======== Net loss per common share: Basic and diluted $(0.39) $(0.55) $(0.90) $(1.10) ====== ====== ====== ====== Shares used in the calculation of net loss per common share: Basic and diluted 39,046 38,421 38
'/>"/>

SOURCE Neurocrine Biosciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer